Kirsten Flowers - Nov 9, 2023 Form 4 Insider Report for Comera Life Sciences Holdings, Inc. (CMRA)

Role: Director
Signature: /s/ Ryan M. Rourke Reed, Attorney-in-Fact
Stock symbol: CMRA
Transactions as of: Nov 9, 2023
Transactions value $: $0
Form type: 4
Date filed: 11/14/2023, 04:31 PM
Previous filing: Sep 1, 2023
Next filing: Jun 10, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CMRA	Stock Option (Right to Purchase)	Award	$0	+111K		$0.00	111K	Nov 9, 2023	Common Stock	111K	$0.32	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Granted pursuant to the Comera Life Sciences Holdings, Inc. 2022 Equity and Incentive Plan. The options were fully vested on the date of grant.
F2	In furtherance of the registrant's cash conservation efforts, the options were granted in lieu of the annual cash retainer and committee fees due to non-employee directors for the quarter ended September 30, 2023, in accordance with the registrant's February 2023 temporary modification to its non-employee director compensation plan. This option was issued to the reporting person in lieu of retainer fees of $14,792. For more information related to the registrant's non-employee director compensation plan and the February 2023 temporary modification, see the registrant's Annual Report on Form 10-K for the year ended December 31, 2022.

Content

Granted pursuant to the Comera Life Sciences Holdings, Inc. 2022 Equity and Incentive Plan. The options were fully vested on the date of grant.

In furtherance of the registrant's cash conservation efforts, the options were granted in lieu of the annual cash retainer and committee fees due to non-employee directors for the quarter ended September 30, 2023, in accordance with the registrant's February 2023 temporary modification to its non-employee director compensation plan. This option was issued to the reporting person in lieu of retainer fees of $14,792. For more information related to the registrant's non-employee director compensation plan and the February 2023 temporary modification, see the registrant's Annual Report on Form 10-K for the year ended December 31, 2022.